Company

Marinomed at a glance

Marinomed Biotech AG is a biopharmaceutical company which was founded in 2006 as a spin-off of the University of Veterinary Medicine Vienna. Since then, the Company has grown successfully to around 50 employees in 2023. In February 2019, Marinomed went public at the Vienna Stock Exchange. Since 2020, the Company has been based at its new company site in Korneuburg, Lower Austria.

Scientific expertise

Marinomed's mission is to develop innovative treatments for indications in virology and immunology.Based on the virus-blocking properties of Carragelose, the Company has developed a portfolio of marketed OTC products for the treatment of viral respiratory infections. In 2023, the portfolio was expanded in the immunology segment with an allergen-blocking nasal spray and moisturizing eye drops. The solubilization technology Marinosolv is used in the Company's own product candidates and is also made available to external customers through Solv4U technology partnerships. The active pipeline includes several product candidates in late-stage development, some of which have already been outlicensed to partners for commercialization.

Experienced management & dedicated team

Marinomed is led by a management team with strong expertise and an extensive track record in virology, infectious diseases, allergies, immunology, molecular biology, finance, M&A and business development. A Scientific Advisory Board and a Supervisory Board, composed of high-profile international experts, support the management team. At the heart of the Company are the highly qualified employees, who drive Marinomed's innovations with creativity and dedication.

Lean business model

Marinomed focuses on the validation of innovative therapeutic approaches, preclinical and clinical drug development, and subsequent outlicensing to partners. For the OTC portfolio, Marinomed also organizes production through qualified manufacturers. Marinomed's pharmaceutical partner companies, in turn, handle the late-stage clinical development, regulatory approval and marketing of the therapeutics around the world. This allows Marinomed to focus on its core competences of research and development and to maintain a lean business model.

Stakeholders

Marinomed is committed to the highest standards of transparency and maintains an open dialogue with its customers, shareholders, partners, and employees. Sustainable development and consistent improvement in environmental, social and governance (ESG) areas is a key priority for Marinomed.

Marinomed Corporate Presentation

History

New products and partnerships

  • Clinical data allows extension of Carragelose use into allergic indications
  • Introduction of new moisturizing eye drops and allergen-blocking nasal spray
  • Market authorization in Mexico and new distribution partnership in southeast Asia
  • Solv4U: First long-term partnership with Shanghai-based SPH Sine Pharmaceutical Laboratories Co. Ltd.

Deal with Procter & Gamble

  • Entered one of the most important license agreements for Carragelose® with Procter & Gamble for the U.S.
  • Received US-patent for the Marinosolv® technology
  • First successful year on the market for Solv4U technology partnerships

Carragelose® effective against SARS-CoV-2 and first deal for Marinosolv®

  • Positive clinical data against SARS-CoV-2
  • Encouraging clinical data for Tacrosolv
  • First international deal for the Marinosolv platform with USD 2 million down payment
  • Launch of Solv4U business area

COVID, Marinosolv® patent & new headquarter in Korneuburg

  • Two clinical trials of Carragelose nasal sprays for the treatment and prevention of COVID-19 initiated after successful in vitro results against SARS-CoV-2
  • Marinosolv platform receives patent for the generation of aqueous solutions from insoluble compounds
  • Implementation of new Marinomed headquarter in Korneuburg, AT

IPO & Validation of Marinosolv® technology

  • IPO in February, quotation in the prime market segment at Vienna Stock Exchange
  • Clinical validation of the Marinosolv® platform with successful completion of phase III pivotal study for Budesolv
  • Award: Eva Prieschl-Grassauer wins Börsianer Salon participant of the year 2019

R&D advances

  • Certification of a new Carragelose® nasal spray with decongestant properties
  • Start of phase III clinical study for the flagship product Budesolv

Stock corporation & Budesolv flagship product

  • Change of legal form to a stock corporation
  • Issue of a convertible bond with a conversion option in the event of an IPO
  • Preparation of a phase III clinical study for the flagship product Budesolv

Marinosolv® development

  • Development of and feasibility study for the Marinosolv® technology platform
  • Completion of a joint round of funding involving aws Mittelstandsfonds Beteiligungs GmbH & Co KG, Invest Unternehmensbeteiligungs AG, together with private investors from the management team and company environment
  • Winner of the Houska prize in the category "Research & development KMU".

Start: Carragelose®-business grows

  • Further product launches and sales partnerships

Carragelose®-business network established

  • Approval in 22 additional countries
  • Development of an independent sales network with outsourced production and logistics begins
  • First-time investment by ARAX Capital Partners (atypical silent partner)

  • Licensing partnership with Boehringer Ingelheim, initially for 54 countries

  • Market launch of the first Carragelose® product and equity investment by Acropora

Carragelose® development

  • Development of the virus-blocking compound Carragelose® derived from red seaweed

Foundation

  • Foundation and start-up financing for Marinomed Biotechnologie GmbH as a spin-off from the University of Veterinary Medicine in Vienna
  • seed investment via aws, investment by Acropora